University of Illinois Chicago

Chicago, Illinois, US

The University of Illinois Chicago (UIC) is Chicago's only public R1 research university and home to one of the nation's most community-engaged urban academic health enterprises, with half a billion dollars in sponsored research.

UIC researchers are advancing discoveries across the life sciences, engineering, computer science, energy, manufacturing, public health, biomedical and other fields. Our scientists are supported by funding from the National Institutes of Health, National Science Foundation, U.S. Department of Energy, and other federal agencies. Through UI Health, UIC offers a major academic health system with deep expertise in translational research, clinical trials, health information sciences and community-engaged healthcare. Beyond campus, UIC collaborates extensively with industry, other universities, national laboratories, government agencies, healthcare systems, and nonprofit organizations to translate research into real-world impact. From cutting-edge core facilities and specialized research infrastructure to world-class faculty and interdisciplinary research centers, UIC provides partners with access to a uniquely urban innovation ecosystem designed to accelerate discovery, commercialization and societal benefit.

Top industry applications

Halo’s AI pipeline combines publication data and faculty input to determine the industry applications with greatest concentration of publishing faculty. It then surfaces those with the strongest industry collaboration evidence.

Medicine

Pharmaceuticals and drug delivery

UIC scientists are developing novel antibiotics, antivirals, and cancer therapeutics—including bacterial ribosome-targeting depsipeptides, SARS-CoV-2 protease inhibitors, and macrophage-reprogramming HDAC6 inhibitors—to combat drug resistance and aggressive tumors. They are pairing these drug candidates with advanced delivery platforms such as pH-responsive nanocarriers, programmable RNA-gradient hydrogels, and transdermal breast-skin patches to minimize systemic toxicity and enable localized gene and small-molecule therapy. Together, these pipelines target urgent pharmaceutical markets in antimicrobial resistance, precision oncology, and next-generation biologics.

Medicine

Oncology & cancer therapeutics

UIC researchers are unlocking new therapeutic avenues against therapy-resistant breast, lung, and pancreatic cancers by targeting ceramide signaling, tumor microenvironment reprogramming, and novel protein degraders. They are translating precision oncology into practice through AI-guided pharmacogenomics, circulating tumor cell technologies, and molecular tumor boards that address unmet clinical needs. By embedding equity-focused interventions and biomarker-driven strategies into drug discovery, the university is advancing commercially viable solutions for diverse patient populations and health systems.

Medicine

Infectious disease & antimicrobials

University of Illinois Chicago researchers are advancing a diverse pipeline of anti-infectives, from ribosome-targeting natural-product antibiotics and broad-spectrum SARS-CoV-2 and influenza inhibitors to novel antitubercular agents that address escalating antimicrobial resistance. They complement drug discovery with AI-powered viral genomics, wastewater epidemiology, and data-driven stewardship programs that reduce hospital costs and optimize antibiotic use. The university also leads implementation-science efforts in HIV prevention and care, deploying telemedicine and community interventions to reach incarcerated and high-risk populations.

Energy & natural resources

Energy storage systems

UIC researchers are engineering next-generation battery chemistries—including lithium-air, lithium-carbon dioxide, and sodium solid-state systems—through the George Crabtree Institute for Discovery and a $62.5 million DOE Energy Storage Research Alliance led by neighboring Argonne National Laboratory. Faculty with joint UIC–Argonne appointments bridge fundamental electrochemistry with applied device design, while spinoff AllCell Technologies (co-founded by UIC faculty) commercializes thermal-management solutions for lithium-ion battery packs. This deep integration with the national laboratory ecosystem and a growing battery-industry corridor positions UIC as a partner for companies developing safer, more sustainable energy storage at scale.

Medicine

Cardiovascular health

UIC engineers and clinicians are advancing wearable hemodynamic rings and cuffless blood-pressure monitors that enable continuous, at-home cardiovascular tracking for diabetes and heart-failure patients. They are also deploying machine-learning ECG screeners and predictive analytics for transcatheter valve procedures to catch disease earlier and optimize structural-heart interventions. Together, these technologies address real-world gaps in remote patient monitoring, maternal cardiovascular care, and health-equity markets.

Medicine

Medical diagnostics

University of Illinois Chicago researchers are advancing medical diagnostics through AI-powered imaging and computational pathology, including machine-learning models that detect uveal melanoma, classify retinal diseases via OCT, and identify predictive histology biomarkers for pancreatic and renal cancers. They are also developing point-of-care technologies—such as wearable hemodynamic rings, urine-based electrochemical biosensors for breast cancer, and microfluidic laser-scribed platforms—that enable rapid, low-cost screening in underserved populations. Combined with clinical NLP tools that reduce diagnostic errors and opioid misuse in emergency departments, this portfolio offers scalable commercial solutions for precision oncology, ophthalmology, and acute care.

Medicine

Medical imaging

University of Illinois Chicago engineers and clinicians are deploying artificial intelligence to interpret OCT, fundus, and ultrasound images for conditions such as diabetic retinopathy, uveal melanoma, and retinopathy of prematurity, reducing reliance on scarce specialists and enabling point-of-care screening. Complementing these AI tools, the team is advancing novel MRI and photoacoustic technologies that deliver non-invasive, high-resolution maps of tissue structure and blood flow for neurology, oncology, and dermatology applications. Together, these platforms address growing demand for faster, more accessible diagnostic workflows that lower costs and improve outcomes in both academic and community care settings.

Medicine

Neurology & neurological disease

University of Illinois Chicago researchers are harnessing large language models and multimodal machine learning to mine electronic health records, enabling earlier detection and precise phenotyping of Alzheimer’s, multiple sclerosis, and stroke. They are translating advances in brain imaging, blood-based biomarkers, and neuromodulation into practical tools for predicting motor recovery, guiding rehabilitation, and slowing neurodegenerative disease progression. This creates clear commercial pathways in digital diagnostics, remote patient monitoring, and precision neurology therapeutics.

Last updated by Halo AI Sep 11, 2026. Please verify key information.

OpenAlex

For general inquiries

Avi Mayerhoff

Director of Corporate Partnerships, University of Illinois Chicago

Have a specific need?
Post a free request to University of Illinois Chicago faculty.

Top industry applications

Pharmaceuticals and drug deliveryOncology & cancer therapeuticsInfectious disease & antimicrobialsEnergy storage systemsCardiovascular healthMedical diagnosticsMedical imagingNeurology & neurological disease